Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Oncolytic viruses constitute a promising therapy against malignant gliomas (MGs). However, virus-induced type I IFN greatly limits its clinical application. The kinase mammalian target of rapamycin (mTOR) stimulates type I IFN production via phosphorylation of its effector proteins, 4E-BPs and S6Ks. Here we show that mouse embryonic fibroblasts and mice lacking S6K1 and S6K2 are more susceptible to vesicular stomatitis virus (VSV) infection than their WT counterparts as a result of an impaired type I IFN response. We used this knowledge to employ a pharmacoviral approach to treat MGs. The highly specific inhibitor of mTOR rapamycin, in combination with an IFN-sensitive VSV-mutant strain (VSV ΔM51 ), dramatically increased the survival of immunocompetent rats bearing MGs. More importantly, VSV ΔM51 selectively killed tumor, but not normal cells, in MG-bearing rats treated with rapamycin. These results demonstrate that reducing type I IFNs through inhibition of mTORC1 is an effective strategy to augment the therapeutic activity of VSV ΔM51 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“Recent evidence implicates the PI3K/mammalian target of rapamycin (mTOR) signaling pathway as one of the main oncogenic signaling pathways whose deregulation may underlie gliomagenesis (6, 7).”
BackgroundDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Viruses and interferon: a fight for supremacy
Katze, M. G., He, Y., & Gale, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri888 · Cited by 1,419 · cited 1×
“Oncogenic transformation is associated with a deficient type I IFN response, which constitutes the first line of defense against virus infection (14, 15).”
Background
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationJaramillo, M., Gomez, M. A., Larsson, O., Shio, M. T., Topisirovic, I., Contreras, I., Luxenburg, R., Rosenfeld, A., Colina, R., McMaster, R. W., et al. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.03.008 · Cited by 171
“Synthesis of type I IFN (IFN-a and IFN-b) is regulated by mTORC1 and its downstream targets p70 ribosomal S6 protein kinases 1 and 2 (S6K1/2) (Alain et al., 2010; Cao et al., 2008), and 4E-BP1/2 (Colina et al.”
BackgroundSelf-citationHoang, H.-D., Graber, T. E., Jia, J.-J., Vaidya, N., Gilchrist, V. H., Xiang, X., Li, W., Cowan, K. N., Gkogkas, C. G., Jaramillo, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.072 · Cited by 18
Self-citation
Metadata
- Authors
- Alain, T., Lun, X., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., Zemp, F. J., Lemay, C. G., Roy, D., Bell, J. C., Thomas, G., Kozma, S. C., Forsyth, P. A., Costa-Mattioli, M., & Sonenberg, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-01-04
- Volume
- 107
- Issue
- 4
- Pages
- 1576-1581
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2115983165
- Cited by
- 132
- References
- 4
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. https://app.cochat.ai/papers/10.1073/pnas.0912344107
- The paper
- Alain, T., Lun, X., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., Zemp, F. J., Lemay, C. G., Roy, D., Bell, J. C., Thomas, G., Kozma, S. C., Forsyth, P. A., Costa-Mattioli, M., & Sonenberg, N. (2010). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0912344107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.